Rescinnamine is a naturally derived indole alkaloid associated with the Rauwolfia family of medicinal plants, particularly Rauwolfia serpentina. It was historically developed as an antihypertensive active pharmaceutical ingredient and belongs to the Rauwolfia alkaloid class of centrally acting antiadrenergic agents. Rescinnamine was first approved in 1956 and has subsequently been discontinued in some markets.
Rescinnamine is identified by CAS No. 24815-24-5, molecular formula C35H42N2O9, and molecular weight 634.7160 g/mol. NIST and PubChem independently report these core chemical identifiers.
Rescinnamine API is a purified alkaloid characterized as a methyl ester and indole alkaloid. It is structurally related to reserpine and differs through its trimethoxycinnamic acid ester group. Historical pharmaceutical references describe rescinnamine as a purified ester alkaloid obtained from Rauwolfia species.
Rescinnamine has a complex pentacyclic indole alkaloid structure containing multiple methoxy groups and an ester-linked trimethoxycinnamoyl moiety. PubChem reports an exact mass of 634.28903092 Da, XLogP3-AA of 4.5, 1 hydrogen-bond donor, 10 hydrogen-bond acceptors, 11 rotatable bonds, and topological polar surface area of 118 Ų.
IUPAC Name:
Methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate.
Rescinnamine was developed for the management of hypertension and is classified under the WHO ATC system as a centrally acting antiadrenergic agent within the Rauwolfia alkaloid group.
Historical pharmacological studies reported hypotensive, bradycardic and sedative effects characteristic of Rauwolfia alkaloids.
Because rescinnamine is an older antihypertensive active ingredient and has been discontinued in some regulatory markets, its current commercial pharmaceutical applications may be limited and market-specific.
Available pharmacology databases describe rescinnamine as competing with angiotensin I for binding to angiotensin-converting enzyme, thereby reducing conversion of angiotensin I to angiotensin II. Lower angiotensin II activity can reduce vasoconstriction and aldosterone-mediated effects.
However, NCATS notes that the mechanism of rescinnamine is not definitively established and that its pharmacological activity probably resembles that of reserpine. Historical research also indicates activity involving the sympathetic nervous system.
Therefore, the mechanism should be represented cautiously in technical documentation rather than describing rescinnamine solely as a conventional modern ACE inhibitor.
Quality control for Rescinnamine API can include:
Important: A current universal pharmacopoeial API release specification for rescinnamine was not identified in the authoritative sources reviewed for this page. Therefore, numerical assay, impurity and water limits should be established according to the applicable customer, regulatory and validated manufacturer specification rather than presented as universal limits.
Rescinnamine is historically associated with alkaloids isolated from Rauwolfia species, especially Rauwolfia serpentina. Historical references describe it as a purified ester alkaloid.
Modern API manufacturing and quality control may involve controlled raw-material sourcing, extraction or chemical processing as applicable, purification, crystallization and validated analytical testing. Manufacturing controls should address identity, purity, residual solvents, impurities and stability.
| Property | Value |
|---|---|
| Appearance | Odorless white to cream-colored crystalline powder |
| Molecular Formula | C35H42N2O9 |
| Molecular Weight | 634.7160 g/mol |
| CAS Number | 24815-24-5 |
| Exact Mass | 634.28903092 Da |
| XLogP3-AA | 4.5 |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 11 |
| Topological Polar Surface Area | 118 Ų |
| PubChem CID | 5280954 |
| UNII | Q6W1F7DJ2D |
PubChem describes Rescinnamine as an odorless white to cream-colored crystalline powder, while NIST reports a molecular weight of 634.7160.
Rescinnamine API should be packed in suitable pharmaceutical-grade, well-closed packaging that protects the material from moisture, contamination and unsuitable environmental exposure.
Recommended storage: Store under controlled conditions according to the validated stability data and approved product specification.
A universal official storage temperature specific to the API was not identified in the authoritative sources reviewed; therefore, a numerical storage temperature should not be presented as a universal requirement.
Typical documentation available for pharmaceutical API supply may include:
A reliable Rescinnamine API manufacturer in India should maintain appropriate controls over raw-material qualification, manufacturing consistency, purification, analytical testing and batch traceability.
For this legacy antihypertensive alkaloid, particular attention should be given to verified chemical identity, chromatographic purity, impurity profiling and documentation because current regulatory and market requirements can vary by intended application.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 1.0% |